Biobanking: The foundation of personalized medicine

Current Opinion in Oncology

Volumn 23, Issue 1, 2011, Pages 112-119

  Hewitt, Robert E ^a  

^a NONE   (France)

Author keywords

Biobank; Biospecimen; Critical path; Personalized medicine; Tumour bank

Indexed keywords

BIOLOGICAL MARKER; TUMOR MARKER;

ARTICLE; BIOBANK; CANCER RESEARCH; GENE EXPRESSION; HEALTH CARE FACILITY; HISTOLOGY; HUMAN; INFORMATION SYSTEM; INFORMED CONSENT; LABORATORY AUTOMATION; MEDICAL ETHICS; PATIENT SAFETY; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RNA DEGRADATION;

BIOLOGICAL SPECIMEN BANKS; HUMANS; INDIVIDUALIZED MEDICINE; NEOPLASMS;

EID: 79851509146     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e32834161b8     Document Type: Article

References (39)

1. U.S. Food and Drug Administration. Innovation or stagnation: challenge and opportunity on the critical path to new medical products. March 2004. http://www.fda.gov/downloads/ScienceResearch/Special-Topics/ CriticalPathInitiative/CriticalPathOpportunitiesReports/ucm113411.pdf. [Accessed 5 April 2010]
2. U.S. Department of Health and Social Services and U.S. Food and Drug Administration. Critical path opportunities report. March 2006. http://www.fda.gov/ScienceResearch/SpecialTopics/CriticalPathInitiative/default. htm.
3. Khleif SN, Doroshow JH, Hait WN. AACR-FDA-NCI Cancer Biomarkers Collaborative Consensus Report: advancing the use of biomarkers in cancer drug development. Clin Cancer Res 2010; 16:3299-3318.
4. Cambon-Thomsen A, Rial-Sebbag E, Knoppers BM. Trends in ethical and legal frameworks for the use of human biobanks. Eur Respir J 2007; 30:373-382. (Pubitemid 47194191)
5. Kauffmann F, Cambon-Thomsen A. Tracing biological collections: between books and clinical trials. JAMA 2008; 299:2316-2318. (Pubitemid 351724399)
6. Gottweis H, Zatloukal K. Biobank governance: trends and perspectives. Pathobiology 2007; 74:206-211. (Pubitemid 47294501)
7. Yuille M, van Ommen G-J, Brechot C, et al. Biobanking for Europe. Brief Bioinform 2008; 9:14-24.
8. Bevilacqua G, Bosman F, Dassesse T. The role of the pathologist in tissue banking: European Consensus Expert Group Report. Virchows Arch 2010; 456:449-454.
9. Hainaut P, Caboux E, Bevilacqua G, et al. Pathology as the cornerstone of human tissue banking: European Consensus Expert Group Report. Bio-preserv Biobank 2009; 7:157-160.
10. Riegman PHJ, Morente MM, Betsou F, et al. Biobanking for better healthcare. Mol Oncol 2008; 2:213-222.
11. Bell WC, Sexton KC, Grizzle WE. Organizational issues in providing highquality human tissues and clinical information for the support of biomedical research. Methods Mol Biol 2010; 576:1-30.
12. Blow N. Biobanking: freezer burn. Nature Methods 2009; 6:173-178.
13. Silberman S. Libraries of Flesh: the sorry state of human tissue storage. Wired Magazine, June 2010. http://www.wired.com/magazine/2010/05/ff-bio-banks/ all/1.
14. Hughes S, Barnes RO, Watson PH. Biospecimen use in cancer research over two decades. Biopreserv Biobank 2010; 8:89-97.
15. MooreHM, Compton CC,LimMD, et al.2009 Biospecimen research network symposium: advancing cancer research through biospecimen science. Cancer Res 2009; 69:6770-6772.
16. Biospecimen Research Database: a joint effort of the Biospecimen Research Network, the RAND Corporation, and the National Cancer Institute Center for Bioinformatics research. https://brd.nci.nih.gov/BRN/brnHome.seam.
17. Yuille M, Illig T, Hveem K, et al. Laboratory management of samples in biobanks: European Consensus Expert Group Report. Biopreserv Biobank 2010; 8:65-69.
18. Guerin JS, Murray DW, McGrath MM. Molecular Medicine Ireland Guidelines for standardized biobanking. Biopreservat Biobank 2010; 8:3-63.
19. Barnes MG, Grom AA, Griffin TA, et al. Gene expression profiles from peripheral blood mononuclear cells are sensitive to short processing delays. Biopreserv Biobank 2010; 8:153-162.
20. Betsou F, Lehmann S, Ashton G. Standard preanalytical coding for biospecimens: defining the sample PREanalytical Code. Cancer Epidemiol Biomarkers Prev 2010; 19:OF1-OF8.
21. Betsou F, Barnes R, Burke T, et al. Human biospecimen research: experimental protocol and quality control tools. Cancer Epidemiol Biomarkers Prev 2009; 18:1017-1025.
22. Betsou F, Rimm DL, Watson PH, et al. What are the biggest challenges and opportunities for biorepositories in the next three to five years? Biopreserv Biobank 2010; 8:81-88.
23. Vaught J, Baust JG, Heacox AE, et al. What are three actionable strategies to improve quality in biomedical research? Biopreserv Biobank 2010; 8:121-125.
24. Baust JG, Gao D, Baust JM. Cryopreservation: an emerging paradigm change. Organogenesis 2009; 5:90-96.
25. Vaught JB, Caboux E, Hainaut P. International efforts to develop biospecimen best practices. Cancer Epidemiol Biomarkers Prev 2010; 19:912-915.
26. Wichmann E. Need for guidelines for standardized biobanking. Biopreserv Biobank 2010; 8:1.
27. Betsou F, Luzergues A, Carter A, et al. Towards norms for accreditation of biobanks for human health and medical research: compilation of existing guidelines into an ISO certification/accreditation norm-compatible format. Qual Assurance J 2007; 11:221-294.
28. Vaught J, Kelly A, Hewitt R. A review of international biobanks and networks: success factors and key benchmarks. Biopreserv Biobank 2009; 7:143-150.
29. Watson PH, Wilson-McManus JE, Barnes RO. Evolutionary concepts in biobanking: the BC BioLibrary. J Trans Med 2009; 7:95.
30. Lee D, Lee Y. The Korea National Research Resource Center. Biopreserv Biobank 2009; 7:137-142.
31. Watson RWG, Kay EW, Smith D. Integrating biobanks: addressing the practical and ethical issues to deliver a valuable tool for cancer research. Nature 2010; 10:646-651.
32. Knoppers BM, Fortier I, Legault D, Burton P. The Public Population Project in Genomics (P3G): a proof of concept? Eur J Hum Genet 2008; 16:664-665. (Pubitemid 351753361)
33. Editorial. Biobanks need pharma. Nature 2009; 461:448.
34. Pálsson G. The rise and fall of a biobank: the case of Iceland. In: Gottweis H, Petersen A (editors). Biobanks. Governance in comparative perspective. 1st ed. London & New York: Routledge; 2008. pp. 41-55.
35. Hansson MG. Ethics and biobanks. Br J Cancer 2009; 100:8-12.
36. ICH Harmonised tripartite Guideline (2007). Definitions for genomic biomarkers, pharmacogenomics, pharmacogenetics, genomicdataand samplecoding categories, E15. vol. 73. The US Federal Register 2008. pp. 19074-19076. http://www.ich.org/LOB/media/MEDIA3383.pdf.
37. Gottweis H, Lauss G. Biobank governance in the postgenomic age. Personal Med 2010; 7:187-195.
38. Gottweis H. Biobanks in action: new strategies in the governance of life. In: Gottweis H, Petersen A, editors. Biobanks. Governance in comparative perspective. 1st edition. London & New York: Routledge; 2008. pp. 22-38.
39. Hewitt R, Watson PH, Dhir R, et al. Timing of consent for the research use of surgically removed tissue: is postoperative consenting acceptable? Cancer 2009; 115:4-9.